Oncopeptides

company

About

Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€30M
Industries
Biotechnology,Clinical Trials,Pharmaceutical
Founded date
Jan 1, 2000
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
sto:ONCO

Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015.
Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
€30M kr2.48B
Oncopeptides has raised a total of €30M kr2.48B in funding over 2 rounds. Their latest funding was raised on Nov 25, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 25, 2022 Post-IPO Debt €30M 1 European Investment Bank Detail
Sep 7, 2022 Grant kr5M 1 Vinnova Detail
Mar 10, 2021 Post-IPO Equity kr1.10B 2 Detail
Jun 28, 2019 Post-IPO Equity kr727M Detail
Mar 2, 2017 IPO kr649M Detail

Investors

Number of Lead Investors
Number of Investors
2
5
Oncopeptides is funded by 5 investors. European Investment Bank and Vinnova are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Post-IPO Debt
Vinnova Yes Grant
Artisan Partners Post-IPO Equity
Bain Capital Post-IPO Equity
Industrifonden Series A

Employee Profiles

Number of Employee Profiles
11
Oncopeptides has 11 current employee profiles, including Board member Brian Stuglik
Board member
Board member
Executive
Executive
Board member